An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.
Identifieur interne : 003182 ( Main/Exploration ); précédent : 003181; suivant : 003183An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.
Auteurs : Michelle Vichnin [France] ; Paolo Bonanni ; Nicola P. Klein ; Suzanne M. Garland ; Stan L. Block ; Susanne K. Kjaer ; Heather L. Sings ; Gonzalo Perez ; Richard M. Haupt ; Alfred J. Saah ; Fabio Lievano ; Christine Velicer ; Rosybel Drury ; Barbara J. KuterSource :
- The Pediatric infectious disease journal [ 1532-0987 ] ; 2015.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Effets secondaires indésirables des médicaments (anatomopathologie), Effets secondaires indésirables des médicaments (épidémiologie), Enfant, Femelle, Grossesse, Humains, Infections à papillomavirus (), Jeune adulte, Mâle, Surveillance post-commercialisation des produits de santé, Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18 (administration et posologie), Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18 (effets indésirables).
- MESH :
- administration et posologie : Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18.
- anatomopathologie : Effets secondaires indésirables des médicaments.
- effets indésirables : Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18.
- épidémiologie : Effets secondaires indésirables des médicaments.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Femelle, Grossesse, Humains, Infections à papillomavirus, Jeune adulte, Mâle, Surveillance post-commercialisation des produits de santé.
English descriptors
- KwdEn :
- Adolescent, Adult, Child, Drug-Related Side Effects and Adverse Reactions (epidemiology), Drug-Related Side Effects and Adverse Reactions (pathology), Female, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (administration & dosage), Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (adverse effects), Humans, Male, Middle Aged, Papillomavirus Infections (prevention & control), Pregnancy, Product Surveillance, Postmarketing, Young Adult.
- MESH :
- chemical , administration & dosage : Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18.
- chemical , adverse effects : Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18.
- epidemiology : Drug-Related Side Effects and Adverse Reactions.
- pathology : Drug-Related Side Effects and Adverse Reactions.
- prevention & control : Papillomavirus Infections.
- Adolescent, Adult, Child, Female, Humans, Male, Middle Aged, Pregnancy, Product Surveillance, Postmarketing, Young Adult.
Abstract
A quadrivalent human papillomavirus (HPV4) type 6/11/16/18 vaccine (GARDASIL/SILGARD®) has been licensed in many countries around the world for the prevention of cervical, vulvar, vaginal, and anal cancers and precancers, as well as external genital warts causally related to HPV types 6/11/16/18. Across 7 phase 3 clinical trials involving more than 29,000 males and females ages 9-45 years, vaccination was generally well tolerated. Because of its expected public health benefit in reducing cervical cancer and other HPV-related diseases, the vaccine has been implemented in the national vaccination programs of several countries, with over 178 million doses distributed worldwide.
DOI: 10.1097/INF.0000000000000793
PubMed: 26107345
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002A21
- to stream PubMed, to step Curation: 002951
- to stream PubMed, to step Checkpoint: 002951
- to stream Ncbi, to step Merge: 002755
- to stream Ncbi, to step Curation: 002755
- to stream Ncbi, to step Checkpoint: 002755
- to stream Main, to step Merge: 003183
- to stream Main, to step Curation: 003182
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.</title><author><name sortKey="Vichnin, Michelle" sort="Vichnin, Michelle" uniqKey="Vichnin M" first="Michelle" last="Vichnin">Michelle Vichnin</name><affiliation wicri:level="3"><nlm:affiliation>From the *Merck & Co., Inc., Kenilworth, New Jersey; †University of Florence, Florence, Italy; ‡Kaiser Permanente Vaccine Study Center, Oakland, California; §The Royal Women's' Hospital, Murdoch Childrens Research Institute, University of Melbourne, Parkville, Victoria, Australia; ¶Kentucky Pediatric Research, Inc., Bardstown, Kentucky; ‖Danish Cancer Society Research Center, Copenhagen, Denmark; **Department of Gynaecology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; ††Universidad del Rosario, Bogota, Colombia; and ‡‡Sanofi Pasteur MSD, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>From the *Merck & Co., Inc., Kenilworth, New Jersey; †University of Florence, Florence, Italy; ‡Kaiser Permanente Vaccine Study Center, Oakland, California; §The Royal Women's' Hospital, Murdoch Childrens Research Institute, University of Melbourne, Parkville, Victoria, Australia; ¶Kentucky Pediatric Research, Inc., Bardstown, Kentucky; ‖Danish Cancer Society Research Center, Copenhagen, Denmark; **Department of Gynaecology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; ††Universidad del Rosario, Bogota, Colombia; and ‡‡Sanofi Pasteur MSD, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bonanni, Paolo" sort="Bonanni, Paolo" uniqKey="Bonanni P" first="Paolo" last="Bonanni">Paolo Bonanni</name></author><author><name sortKey="Klein, Nicola P" sort="Klein, Nicola P" uniqKey="Klein N" first="Nicola P" last="Klein">Nicola P. Klein</name></author><author><name sortKey="Garland, Suzanne M" sort="Garland, Suzanne M" uniqKey="Garland S" first="Suzanne M" last="Garland">Suzanne M. Garland</name></author><author><name sortKey="Block, Stan L" sort="Block, Stan L" uniqKey="Block S" first="Stan L" last="Block">Stan L. Block</name></author><author><name sortKey="Kjaer, Susanne K" sort="Kjaer, Susanne K" uniqKey="Kjaer S" first="Susanne K" last="Kjaer">Susanne K. Kjaer</name></author><author><name sortKey="Sings, Heather L" sort="Sings, Heather L" uniqKey="Sings H" first="Heather L" last="Sings">Heather L. Sings</name></author><author><name sortKey="Perez, Gonzalo" sort="Perez, Gonzalo" uniqKey="Perez G" first="Gonzalo" last="Perez">Gonzalo Perez</name></author><author><name sortKey="Haupt, Richard M" sort="Haupt, Richard M" uniqKey="Haupt R" first="Richard M" last="Haupt">Richard M. Haupt</name></author><author><name sortKey="Saah, Alfred J" sort="Saah, Alfred J" uniqKey="Saah A" first="Alfred J" last="Saah">Alfred J. Saah</name></author><author><name sortKey="Lievano, Fabio" sort="Lievano, Fabio" uniqKey="Lievano F" first="Fabio" last="Lievano">Fabio Lievano</name></author><author><name sortKey="Velicer, Christine" sort="Velicer, Christine" uniqKey="Velicer C" first="Christine" last="Velicer">Christine Velicer</name></author><author><name sortKey="Drury, Rosybel" sort="Drury, Rosybel" uniqKey="Drury R" first="Rosybel" last="Drury">Rosybel Drury</name></author><author><name sortKey="Kuter, Barbara J" sort="Kuter, Barbara J" uniqKey="Kuter B" first="Barbara J" last="Kuter">Barbara J. Kuter</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26107345</idno><idno type="pmid">26107345</idno><idno type="doi">10.1097/INF.0000000000000793</idno><idno type="wicri:Area/PubMed/Corpus">002A21</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A21</idno><idno type="wicri:Area/PubMed/Curation">002951</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002951</idno><idno type="wicri:Area/PubMed/Checkpoint">002951</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002951</idno><idno type="wicri:Area/Ncbi/Merge">002755</idno><idno type="wicri:Area/Ncbi/Curation">002755</idno><idno type="wicri:Area/Ncbi/Checkpoint">002755</idno><idno type="wicri:Area/Main/Merge">003183</idno><idno type="wicri:Area/Main/Curation">003182</idno><idno type="wicri:Area/Main/Exploration">003182</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.</title><author><name sortKey="Vichnin, Michelle" sort="Vichnin, Michelle" uniqKey="Vichnin M" first="Michelle" last="Vichnin">Michelle Vichnin</name><affiliation wicri:level="3"><nlm:affiliation>From the *Merck & Co., Inc., Kenilworth, New Jersey; †University of Florence, Florence, Italy; ‡Kaiser Permanente Vaccine Study Center, Oakland, California; §The Royal Women's' Hospital, Murdoch Childrens Research Institute, University of Melbourne, Parkville, Victoria, Australia; ¶Kentucky Pediatric Research, Inc., Bardstown, Kentucky; ‖Danish Cancer Society Research Center, Copenhagen, Denmark; **Department of Gynaecology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; ††Universidad del Rosario, Bogota, Colombia; and ‡‡Sanofi Pasteur MSD, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>From the *Merck & Co., Inc., Kenilworth, New Jersey; †University of Florence, Florence, Italy; ‡Kaiser Permanente Vaccine Study Center, Oakland, California; §The Royal Women's' Hospital, Murdoch Childrens Research Institute, University of Melbourne, Parkville, Victoria, Australia; ¶Kentucky Pediatric Research, Inc., Bardstown, Kentucky; ‖Danish Cancer Society Research Center, Copenhagen, Denmark; **Department of Gynaecology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; ††Universidad del Rosario, Bogota, Colombia; and ‡‡Sanofi Pasteur MSD, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bonanni, Paolo" sort="Bonanni, Paolo" uniqKey="Bonanni P" first="Paolo" last="Bonanni">Paolo Bonanni</name></author><author><name sortKey="Klein, Nicola P" sort="Klein, Nicola P" uniqKey="Klein N" first="Nicola P" last="Klein">Nicola P. Klein</name></author><author><name sortKey="Garland, Suzanne M" sort="Garland, Suzanne M" uniqKey="Garland S" first="Suzanne M" last="Garland">Suzanne M. Garland</name></author><author><name sortKey="Block, Stan L" sort="Block, Stan L" uniqKey="Block S" first="Stan L" last="Block">Stan L. Block</name></author><author><name sortKey="Kjaer, Susanne K" sort="Kjaer, Susanne K" uniqKey="Kjaer S" first="Susanne K" last="Kjaer">Susanne K. Kjaer</name></author><author><name sortKey="Sings, Heather L" sort="Sings, Heather L" uniqKey="Sings H" first="Heather L" last="Sings">Heather L. Sings</name></author><author><name sortKey="Perez, Gonzalo" sort="Perez, Gonzalo" uniqKey="Perez G" first="Gonzalo" last="Perez">Gonzalo Perez</name></author><author><name sortKey="Haupt, Richard M" sort="Haupt, Richard M" uniqKey="Haupt R" first="Richard M" last="Haupt">Richard M. Haupt</name></author><author><name sortKey="Saah, Alfred J" sort="Saah, Alfred J" uniqKey="Saah A" first="Alfred J" last="Saah">Alfred J. Saah</name></author><author><name sortKey="Lievano, Fabio" sort="Lievano, Fabio" uniqKey="Lievano F" first="Fabio" last="Lievano">Fabio Lievano</name></author><author><name sortKey="Velicer, Christine" sort="Velicer, Christine" uniqKey="Velicer C" first="Christine" last="Velicer">Christine Velicer</name></author><author><name sortKey="Drury, Rosybel" sort="Drury, Rosybel" uniqKey="Drury R" first="Rosybel" last="Drury">Rosybel Drury</name></author><author><name sortKey="Kuter, Barbara J" sort="Kuter, Barbara J" uniqKey="Kuter B" first="Barbara J" last="Kuter">Barbara J. Kuter</name></author></analytic><series><title level="j">The Pediatric infectious disease journal</title><idno type="eISSN">1532-0987</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Child</term><term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term><term>Drug-Related Side Effects and Adverse Reactions (pathology)</term><term>Female</term><term>Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (administration & dosage)</term><term>Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (adverse effects)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Papillomavirus Infections (prevention & control)</term><term>Pregnancy</term><term>Product Surveillance, Postmarketing</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Effets secondaires indésirables des médicaments (anatomopathologie)</term><term>Effets secondaires indésirables des médicaments (épidémiologie)</term><term>Enfant</term><term>Femelle</term><term>Grossesse</term><term>Humains</term><term>Infections à papillomavirus ()</term><term>Jeune adulte</term><term>Mâle</term><term>Surveillance post-commercialisation des produits de santé</term><term>Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18 (administration et posologie)</term><term>Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18 (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccin recombinant quadrivalent contre les papillomavirus humains de type 6, 11, 16 et 18</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Papillomavirus Infections</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Child</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pregnancy</term><term>Product Surveillance, Postmarketing</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enfant</term><term>Femelle</term><term>Grossesse</term><term>Humains</term><term>Infections à papillomavirus</term><term>Jeune adulte</term><term>Mâle</term><term>Surveillance post-commercialisation des produits de santé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A quadrivalent human papillomavirus (HPV4) type 6/11/16/18 vaccine (GARDASIL/SILGARD®) has been licensed in many countries around the world for the prevention of cervical, vulvar, vaginal, and anal cancers and precancers, as well as external genital warts causally related to HPV types 6/11/16/18. Across 7 phase 3 clinical trials involving more than 29,000 males and females ages 9-45 years, vaccination was generally well tolerated. Because of its expected public health benefit in reducing cervical cancer and other HPV-related diseases, the vaccine has been implemented in the national vaccination programs of several countries, with over 178 million doses distributed worldwide.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li></region><settlement><li>Lyon</li></settlement></list><tree><noCountry><name sortKey="Block, Stan L" sort="Block, Stan L" uniqKey="Block S" first="Stan L" last="Block">Stan L. Block</name><name sortKey="Bonanni, Paolo" sort="Bonanni, Paolo" uniqKey="Bonanni P" first="Paolo" last="Bonanni">Paolo Bonanni</name><name sortKey="Drury, Rosybel" sort="Drury, Rosybel" uniqKey="Drury R" first="Rosybel" last="Drury">Rosybel Drury</name><name sortKey="Garland, Suzanne M" sort="Garland, Suzanne M" uniqKey="Garland S" first="Suzanne M" last="Garland">Suzanne M. Garland</name><name sortKey="Haupt, Richard M" sort="Haupt, Richard M" uniqKey="Haupt R" first="Richard M" last="Haupt">Richard M. Haupt</name><name sortKey="Kjaer, Susanne K" sort="Kjaer, Susanne K" uniqKey="Kjaer S" first="Susanne K" last="Kjaer">Susanne K. Kjaer</name><name sortKey="Klein, Nicola P" sort="Klein, Nicola P" uniqKey="Klein N" first="Nicola P" last="Klein">Nicola P. Klein</name><name sortKey="Kuter, Barbara J" sort="Kuter, Barbara J" uniqKey="Kuter B" first="Barbara J" last="Kuter">Barbara J. Kuter</name><name sortKey="Lievano, Fabio" sort="Lievano, Fabio" uniqKey="Lievano F" first="Fabio" last="Lievano">Fabio Lievano</name><name sortKey="Perez, Gonzalo" sort="Perez, Gonzalo" uniqKey="Perez G" first="Gonzalo" last="Perez">Gonzalo Perez</name><name sortKey="Saah, Alfred J" sort="Saah, Alfred J" uniqKey="Saah A" first="Alfred J" last="Saah">Alfred J. Saah</name><name sortKey="Sings, Heather L" sort="Sings, Heather L" uniqKey="Sings H" first="Heather L" last="Sings">Heather L. Sings</name><name sortKey="Velicer, Christine" sort="Velicer, Christine" uniqKey="Velicer C" first="Christine" last="Velicer">Christine Velicer</name></noCountry><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Vichnin, Michelle" sort="Vichnin, Michelle" uniqKey="Vichnin M" first="Michelle" last="Vichnin">Michelle Vichnin</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003182 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003182 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26107345
|texte= An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26107345" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |